ALLO Allogene Therapeutics

Allogene Therapeutics Announces October 2020 Virtual Investor Conference Participation

Allogene Therapeutics Announces October 2020 Virtual Investor Conference Participation
EN
01/10/2020

Underlying

ALLOAllogene Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Allogene Therapeutics

 PRESS RELEASE
Free
ALLO Allogene Therap...

Allogene Therapeutics Announces Participation in Upcoming Investor Con...

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in two upcoming investor conferences in the first quarter of 2026. Citi's 2026 Virtual Oncology Leadership SummitWednesday, February 189:15AM PT/12:15PM ET TD Cowen 46th Annual Health Care Conference Tuesday, March 38:50AM P...

February 5, 2026 1 EN
 PRESS RELEASE
Free
ALLO Allogene Therap...

Allogene Therapeutics Positions 2026 as a Program-Defining Year for Sc...

Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T 1H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune Disease Interim Futility Analysis of MRD Clearance from the Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line (1L) Consolidation Large B-Cell Lymphoma (LBCL) Planned for Early Q2 2026Initial Proof-of-Concept for ALLO-329, the Dual CD19/CD70 AlloCAR T Leveraging the Dagger® Technology to Reduce or Eliminate Lymphodepletion in the Treatment of Auto...

January 8, 2026 1 EN
 PRESS RELEASE
Free
ALLO Allogene Therap...

Allogene Therapeutics Reports Favorable Result for Servier in Arbitrat...

Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis Arbitration Ruling Reaffirms Allogene’s Full Control of Cemacabtagene Ansegedleucel (Cema-Cel)Decision Reconfirms Allogene’s Expanded Sub-License Covering EU and UK Rights with Options for Japan and China, Clearing the Path for Allogene to Acquire Full Global Rights 1H 2026 Interim Futility Analysis from the Pivotal Phase 2 ALPHA3 Trial with Cema-Cel in First-Line (1L) Consolidation Large B-Cell Lymphoma (LBCL) Remains on Track SOUTH SAN FRANCISCO, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Allogene T...

December 15, 2025 1 EN
 PRESS RELEASE
Free
ALLO Allogene Therap...

Allogene Therapeutics Announces Participation in Upcoming Investor Con...

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in three upcoming investor conference in November and December. TD Cowen’s Immunology & Inflammation Virtual SummitWednesday, November 121:30PM PT/4:30PM ET Jefferies Global Healthcare Conference in LondonTuesday, November ...

November 10, 2025 1 EN
 PRESS RELEASE
Free
ALLO Allogene Therap...

Allogene Therapeutics Reports Third Quarter 2025 Financial Results and...

Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 Positions Company at the Forefront of MRD-guided, Earlier-Line Oncology TreatmentAdditional Sites in Australia and South Korea Expected to Open in early 2026Scheduled Futility Analysis, Focused on MRD Conversion Between Study Arms, on Track for 1H 2026 Phase 1 RESOLUTION Trial with ALLO-329 in Autoimmune Disease (AID) ALLO-329, a Dual CD19/CD70 CAR, Harness...

November 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch